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For cardiac transplant (CTx) recipients, the recommended everolimus (EVL) dose is 0.75mg bid or 1.5mg bid and the target
trough blood level is 3–8 µg/L. We studied a cohort of 56 CTx patients with chronic kidney disease receiving 0.75mg bid EVL to
maintain blood levels of 5–8ug/L (designated RD group) and a cohort of 51 CTx patients with chronic kidney disease receiving
0.5mg bid to maintain blood levels of 3–5ug/L (designated LD group). The primary endpoint was a composite of death, rejection
and premature EVL discontinuation up to 1 year after introduction of EVL. The primary endpoint was reached by 32% of patients
in the LD group and by 41.1% of patients in the RD group (P = 0.361). Biochemical safety parameters were comparable in both
groups. Our results indicate that low-dose EVL may be as eﬀective and safe as regular dose EVL.
1.Introduction
Theuseofcalcineurininhibitors(CNIs)suchascyclosporine
(CSA) and tacrolimus (TAC) has dramatically increased
medium-term life expectancy after heart transplantation but
has had only limited impact on long-term outcomes for
heart transplant recipients [1]. One of the most important
predictors for patient mortality at >5 years after heart
transplantation is cardiac allograft vasculopathy (CAV),
which accounts for 31% of deaths. Neither cyclosporine
nor tacrolimus has been shown to prevent the development
of CAV [1]. CNI administration also increases the risk of
chronic kidney disease (CKD) [2]. Between 3% and 10%
of cardiac transplant recipients will ultimately develop CKD
stage 5 [3].
The mammalian target of rapamycin (TOR) inhibitor
everolimus (EVL) potentially reduces CAV, while main-
taining the low cellular rejection rates seen with standard
therapy [4]. In addition, EVL allows a marked reduction
of CSA exposure in de novo cardiac transplant recipients,
subsequently leading to an early protection of renal function
[5]. As medical care for cardiac transplant recipients, in
combination with low-dose CSA, EVL is able to achieve a
stable kidney function [6].
The EVL dosage is according to trough blood levels
0.75 or 1.5mg twice daily. Target blood levels are 3 to
8µg/L, with 6 to 8µg/L considered as the optimal range for
most patients [7]. However, tolerability and safety of EVL
therapy remain a concern with medical conditions such as
pneumonitis, eﬀusions, mouth ulcers, edema, and impaired
wound healing [4]. Approximately 5% of cardiac transplant
recipients develop potentially life-threatening lingual edema
under EVL therapy [8]. Further, EVL leads to hyperlipidemia
and dyslipidemia [9, 10].
It is currently not known whether patients would beneﬁt
from a low EVL dose. It was therefore the aim of this cohort
study to compare eﬃcacy and safety of low-dose EVL with
regular dose administration in cardiac transplant recipients.
2.MaterialsandMethods
2.1. Patients. This investigation is based on patients who
were changed from immunosuppressive therapy with CNI,
purine antagonist, and methylprednisolone to EVL plus low-
dose CNI therapy at our clinic between January 2004 and
June 2006. Of 1054 eligible cardiac transplant recipients,
173 received EVL plus low-dose CNI therapy (Figure 1).2 Journal of Transplantation
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Figure 1: Study ﬂow chart.
After exclusion of 21 patients known to be nonadherent
with the immunosuppressive medication and four patients
with psychosyndrome, 148 patients were checked. Seven
patients had less than 2 visits per year and two patients
were younger than 18 years of age. Seven other patients were
already diagnosed as having CAV and 25 patients suﬀered
already from recurrent rejection before conversion to EVL,
for example, more than 3 rejections since their cardiac
transplantation indicating insuﬃcient immunosuppression.
Thus, 107 patients could be included into our data analysis.
Inclusion criteria for conversion to EVL were a serum crea-
tinine concentration >1.6mg/dL (n = 104), neurotoxicity of
CNI inhibitors (n = 2), and a tumour diagnosis (n = 1). Of
the 107 patients, a cohort of 56 patients received a regular
EVL dose (0.75mg bid, designated RD group) to maintain
blood levels to 5–8ug/L. The RD group was switched over
to EVL between January 2004 and December 2004. Due to
concerns about potential side eﬀects of EVL (8), a cohort
of 51 patients who changed to EVL between January 2005
and June 2006 received low doses (0.5mg bid; designated LD
group) to maintain blood levels to 3–5ug/l. After conversion
to EVL, the CSA or TAC dose was reduced gradually in both
groups: on the ﬁrst day of converting to EVL, for safety
reasons CSA or TAC dose was reduced only by 20%. During
the next 4 days, the CSA or TAC dose was further reduced to
achieve an overall reduction of 40%. Purine inhibitors and
methylprednisone were stopped after changing patients to
EVL. All procedures of this investigation were in accordance
with the Helsinki declaration of 1975.
2.2. Data Assessment. In the RD and LD groups, we assessed
patients’ data for up to one year after converting to EVL.
The primary endpoint was a composite endpoint of death,
graft loss, premature EVL discontinuation due to adverse
events, and any event of rejection. Secondary endpoints were
safety parameters determined on the basis of laboratory
evaluations. In detail, we recorded serum concentrations of
triglycerides, total cholesterol, HDL- and LDL-cholesterol,
creatinine, blood urea nitrogen (BUN), white blood cells,
red blood cells, and platelets before converting to EVL (t0)
and at six (t6) and twelve months (t12) after conversion.
Blood trough levels of immunosuppressives were recorded
before conversion (TAC, CSA), and at t1, t3, t6, t9, and t12
(EVL,TAC,CSA). Immunosuppressives were determined by
liquid chromatography tandem mass spectrometry (Waters,
Eschborn, Germany). Hematological parameters were ana-
lyzed by the Cell-Dyn 3700 (Abbott Diagnostics, Wiesbaden,
Germany), whereas the other biochemical parameters were
measured by the Architect ci8000 (Abbott, Wiesbaden,
Germany). Glomerular ﬁltration rate was assessed by the
MDRD formula [11].
2.3. Cardiac Rejection. Generally, we do not perform myo-
cardial biopsies routinely after discharge. We assume a clin-
ically proven rejection that needs a daily cortisone bolus of
1000mg for three days when at least two of the following ﬁve
criteria are present: an echocardiography assessed ejection
fraction <50%, a left ventricular ejection time <200ms, an
isovolumetric relaxation time >60ms, occurrence of septicJournal of Transplantation 3
Table 1: Characteristics of the patients.
Characteristic
1.0mg of
Everolimus
(N = 51)
1.5mg of
Everolimus
(N = 56)
P value
Age (years) 61.9 ±10.65 9 .0 ±11.5 0.170
Sex (% males) 84.3 82.1 0.801
Weight (kg) 81.1 ±12.17 9 .6 ±12.0 0.533
Height (cm) 176 ±7 174 ±8 0.165
Primary reason for
transplantation
Dilated cardiomyopathy (%) 43.1 30.4 0.228
Coronary heart disease (%) 47.1 64.3 0.082
Others (%) 9.8 5.4 0.474
Diabetes mellitus (%) 21.6 23.2 0.512
Time since transplantation
(months) 76.8 ±61.88 0 .7 ±60.0 0.675
Glomerular ﬁltration rate
(mL/min/1.73m2) 34.4 ±11.93 5 .8 ±10.3 0.528
Kind of immunosuppression
after conversion
CSA/EVL (%) 66.7 58.9 0.431
TAC/EVL (%) 33.3 41.7 0.431
hypokinesia and pericardial eﬀusion, and a mean arterial
pressure <65mmHg in parallel with nausea, weakness, and
abdominal or thoracic pain. We assume a clinically proven
severe rejection which needs OKT therapy when cardiac
index is <1.6 L/min/m2 (low output syndrome).
2.4. Statistics. Categorical variables are reported using the
percent of observations. Continuous variables are expressed
as mean and standard deviation (SD). For comparisons of
categorical variables, the two-sided Fisher exact test or the
chi-square were used when appropriate. Comparisons of
continuous variables at baseline and at speciﬁc time points
were performed with the Mann-Whitney test. Time eﬀects
were evaluated using the Friedman test. The Wilcoxon test
was used to assess diﬀerences between groups at speciﬁc time
points. Complication rates were calculated with the Kaplan-
Meier product-limit estimator. The log-rank test was used
in order to test for potential diﬀerences in complication
rates between the study groups. P values < 0.05 (two-tailed
test) were considered statistically signiﬁcant. We used the
statistical software package PASW, version 18 (Chicago, IL,
USA), to perform the analyses. This analysis was designed by
theauthors,whohadfullaccesstothedata,analysedthedata,
and controlled all decisions regarding publication.
3. Results andDiscussion
3.1.BaselinePatients’Characteristics. Baselinecharacteristics
are listed in Table 1. The two groups were comparable
with respect to age, sex, body weight and height, primary
reason for cardiac transplantation, prevalence of diabetes
mellitus, and kidney function. Moreover, the time since
cardiac transplantation and the kind of concomitant CNI
inhibitor administration did not diﬀer between groups. In
the LD group, 33 patients received CSA, whereas 18 patients
received TAC. The corresponding numbers for the RD group
were 34 and 22 patients, respectively. Mean baseline CSA
and TAC levels were within the target range for patients
receiving immunosuppression (CSA: 80–100µg/L;.TAC: 6–
10µg/L). After reduction of the CNI-dose, blood trough
levels of CSA and TAC decreased to a similar degree in both
study groups (Table 2). As one would expect, blood trough
levels of EVL increased less pronounced in the LD group
than in the RD group (Table 2). In the LD group, mean
EVL concentrations were at the lower end of the target range
during follow-up. At t6, mean weekly EVL dose in the LD
and RD groups was 9.0mg (SD: 2.2mg; median: 8.8mg) and
13.5mg (SD: 4.7mg; median: 12.0mg), respectively (P<
0.001). The corresponding values at t12 were 8.8mg (SD:
1.6mg; median: 9.1mg) and 13.3mg (SD: 4.4mg; median:
12.0mg), respectively (P<0.001). Thus, weekly EVL dose
was 50% higher in the RD group than that in the LD group.
3.2.PrimaryEndpoint. Figure 2illustratesaccordingtostudy
group the incidence of the primary endpoint. In the LD and
RD groups, 32.0% and 41.1%, respectively, of patients had
reached the primary endpoint (P = 0.361). Thus, results did
not diﬀer signiﬁcantly between the two groups. Moreover,
the rates of death, premature EVL discontinuation, and
episodes of rejection were similar in both groups (Table 3).
Indetail,therewere2deathsintheRDgroupbutnoneinthe
LD group. Causes of death were noncardiac (traﬃca c c i d e n t )
andCAV.Thenumberofpatientswithadverseeventsleading
to discontinuation of EVL was 23.5% in the LD group and
33.9% in the RD group (P = 0.166). Eight clinically proven
cardiacrejectionsoccurredduringfollow-up.Theprevalence
did not diﬀer between the LD and RD group (Table 3). Of
the 3 patients with cardiac rejection in the RD group, one
patient had EVL blood trough levels below the target range
around the time when the event occurred. Of the 5 patients
withcardiacrejectionintheLDgroup,fourpatientshadEVL
blood trough levels below the target range around the time
when the event occurred.
Three years after converting to EVL, the composite
endpoint was reached by 45.1% of the patients in the LD
group and by 53.6% of the patients in the RD group (P =
0.340). In detail, in the LD group 3 patients had died,
1 patient was retransplanted, 5 had developed a cardiac
rejection,and14hadtodiscontinueEVL.Thecorresponding
valuesfortheRDgroupweredeath(n = 5),cardiacrejection
(n = 3), and EVL discontinuation (n = 23).
3.3. Safety Parameters. In total, there was a trend towards
more adverse events in the RD group than in the LD
group (P = 0.054). Whereas infections were prevalent
in the LD group, edema/dyspnoe and cytopenia were the
most prevalent adverse events in the RD group (Table 3).
A detailed inspection of the adverse events leading to EVL
discontinuation also shows that signiﬁcant more causes of
cytopenia resulted in EVL discontinuation in the RD group4 Journal of Transplantation
Table 2: Time course of immunosuppressive agents in cardiac transplant recipients receiving low-dose EVL (LD) or high-dose EVL (RD).
Parameter T0 T1 T3 T6 T9 T12 P value
Everolimus (µg/L)
LD group — 4.34 ±2.63 3.59±1.44∗∗∗ 3.66±2.06∗∗∗ 3.34±1.22∗∗∗ 3.10±1.02∗∗∗ 0.139
RD group — 5.22 ±2.63 5.76 ±2.53 6.24 ±2.49 5.31 ±1.86 5.28 ±2.01 0.096
CSA (µg/L)
LD group 102.0 ±31.57 0 .1 ±38.85 1 .0 ±15.65 1 .4 ±19.54 7 .8 ±18.84 3 .1 ±13.6 <0.001
RD group 91.3 ±26.16 0 .3 ±30.04 8 .2 ±27.85 0 .6 ±27.54 8 .8 ±22.44 3 .1 ±19.7 <0.001
TAC (µg/L)
LD group 9.10 ±2.10 6.49 ±2.91 5.26 ±1.42 5.74 ±2.36 4.48 ±0.94 4.75 ±1.10 <0.001
RD group 8.88 ±2.14 6.71 ±2.69 4.89 ±1.42 4.68 ±1.28 5.20 ±2.18 5.67 ±1.88 <0.001
∗∗∗Signiﬁcant diﬀerent from RD group at the same time point.
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Figure 2: Cumulative risk of the primary endpoint. The primary endpoint was a composite of death, graft loss, everolimus discontinuation
and rejection.
as in the LD group (Table 3). In contrast, more patients had
to discontinue EVL in the LD group than in the RD group
due to infections. None of the patients had PCR-proven
CMV infection, either in the LD group or in the RD group.
Neither in the LD group nor in the RD group creati-
nine and BUN concentrations increased during follow-up
(Table 4). Lipid parameters and blood cell counts did not
diﬀer between the two study groups at any speciﬁc point of
time. In both study groups, however, trigylcerides and total
cholesterol tended to increase during follow-up.
4. Discussion
The combination of EVL with a reduction in CNI inhibitors
is increasingly used in cardiac transplant recipients [12–14].
There is evidence that this immunosuppressive regimen is
able to maintain the low cellular rejection rates seen with
standard therapy [4, 15] and may protect kidney function
[5, 16]. The present cohort study indicates that low-dose
E V Li sa se ﬀective and safe as regular dose EVL with
respect to a composite endpoint of death, rejection, and
severe adverse events. In addition, measured creatinine levels
showed that kidney function was similar between the two
groups at the end of the follow-up period. To the best of our
knowledge, this is the ﬁrst investigation studying the eﬀects
of low-dose EVL in cardiac transplant recipients. Results are
promising; however, the fact that this is a nonrandomized
study precludes us from any ﬁnal conclusions. Prospective
randomized studies are warranted to conﬁrm eﬃcacy and
safety of low-dose EVL.
There was signiﬁcant disparity in the kind of adverse
events with more infections but less cases of cytopenia in
the LD group than in the RD group. It is well known that
mTORinhibitorssuchasEVLcanresultinmyelosuppression
[9, 10]. This may explain why cytopenia occurred more
often in the LD group than in the RD group. However,
this is obviously not a general EVL eﬀect in cardiac
transplant recipients since mean concentrations of red blood
cells, white blood cells, and platelets were unaﬀected by
the introduction of EVL (Table 4). Although none of the
patients had CMV infections during follow-up, it may be
that several infections were of viral origin in the patients
aﬀected. mTOR inhibitors may aﬀect viral ampliﬁcation
indirectly by blocking cellular proliferation and impairing
the phosphatidylinositol 3-kinase pathway which is crucial
for CMV infection, signalling, and replication [17, 18]. This
may at least in part explain the lower infection rate in the
RD group compared to the LD group. Our data conﬁrm thatJournal of Transplantation 5
Table 3: Adverse events of everolimus (EVL) during 12 months of
Follow-up1.
Adverse event
1.0mg of
EVL
(N = 51)
1.5mg of
EVL
(N = 56)
P value
Patients who discontinued
everolimus treatment before 12
months
Death 0 2 (3.6) 0.272
Graft loss 0 0 >0.999
Lost to follow-up 0 0 >0.999
Adverse events leading to EVL
discontinuation 12 (23.5) 19 (33.9) 0.166
Infection 6 (11.8) 1 (1.8) 0.043
Edema and/or
dyspnoe(total) 5 (7.8) 10 (17.9) 0.105
Lingual edema 0 1 (1.8) 0.523
Diarrhea 0 1 (1.8) 0.523
Epitaxis 1 (2.0) 2 (3.6) 0.523
Cytopenia 0 4 (7.1) 0.048
Urticaria 0 1 (1.8) 0.523
All patients 22 (43.1) 35 (62.5) 0.054
Rejection 5 (9.8) 3 (5.4) 0.307
All adverse events
Infection 10 (19.6) 2 (3.6) 0.009
Edema and/or dyspnoe
(total) 6 (11.8) 19 (33.9) 0.011
Lingual edema 0 2 (3.6) 0.225
Diarrhea 0 3 (5.4) 0.105
Epitaxis 1 (2.0) 0 0.523
Cytopenia 0 5 (8.9) 0.022
Urticaria 0 1 (1.8) 0.523
1Data are presented as numbers and percentages.
many adverse eﬀects under EVL occur early after conversion
[19]. While EVL can result in potentially life-threatening
adverse events [8], some adverse events resolve without
intervention within a few weeks [19]. Nevertheless, the fact
that the total number of adverse events tended to be lower in
the LD group compared with the RD group supports the use
of a low-dose EVL regimen.
The percentage of patients with cardiac rejection was in
the range observed in earlier studies in maintenance car-
diac transplant recipients receiving EVL [13–15]. Although
cardiac rejections did not diﬀer between groups, our data
also indicate that the risk of having an event may increase
at blood EVL levels below 3µg/L. Therefore, eﬀective patient
adherence and a regular control of EVL blood trough levels
are important. Because of the promising results of low-dose
EVL administration and as a compromise regarding the risk
of cardiac rejection, we are currently using an initial EVL
Table 4: Time course of biochemical paramters in cardiac trans-
plant recipients on low-dose EVL (LD) or high-dose EVL (RD).
Parameter T0 T6 T12 P value
LD n = 51;
RD n = 56
LD n = 44;
RD n = 41
LD n = 39;
RD n = 36
Creatinine
(mg/dL)
LD group 2.23 ±0.75 2.06 ±0.87 2.05 ±0.79 0.030
RD group 2.06 ±0.44 2.07 ±0.83 2.08 ±0.84 0.725
BUN (mg/dL)
LD group 99 ±38 81 ±34 78 ±29 0.003
RD group 93 ±37 97 ±51 90 ±41 0.420
Triglycerides
(mg/dL)
LD group 162 ±80 198 ±106 209 ±116 0.006
RD group 182 ±107 254 ±211 253 ±222 0.063
Total cholesterol
(mg/dL)
LD group 206 ±54 216 ±62 222 ±51 0.029
RD group 199 ±50 228 ±63 229 ±56 0.013
HDL-
cholesterol
(mg/dL)
LD group 57.4 ±15.75 7 .0 ±19.05 6 .0 ±16.6 0.639
RD group 52.0 ±15.75 9 .4 ±17.75 9 .8 ±15.4 <0.001
LDL-cholesterol
(mg/dL)
LD group 121 ±45 125 ±44 123 ±41 0.815
RD group 119 ±33 129 ±42 124 ±43 0.611
White blood
cells (106/L)
LD group 7.58 ±3.40 6.60 ±1.89 6.36 ±2.04 0.202
RD group 7.23 ±1.77 7.20 ±1.57 7.11 ±1.78 0.268
Red blood cells
(1012/L)
LD group 4.11 ±0.61 4.32 ±0.64 4.48 ±0.74 <0.001
RD group 4.15 ±0.59 4.35 ±0.69 4.44 ±0.73 0.076
Platelets (109/L)
LD group 218 ±66 219 ±65 220 ±73 0.819
RD group 223 ±77 224 ±59 220 ±52 0.467
dose of 1.25mg daily (0.5 and 0.75, resp.). Our target EVL
blood level is now 4.0−6.5µg/L.
Due to the inclusion criteria, the vast majority of our
patients had already had poor kidney function when they
changed over to EVL. Recent data indicate only a modest
improvement in kidney function in patients with already
existing renal dysfunction [16, 20]. In line with these
earlier ﬁndings, our data analysis indicates that neither
regular dose EVL nor low-dose EVL resulted in a clinical
relevant improvement in kidney function during follow-up,6 Journal of Transplantation
as measured by serum creatinine levels. There is however
evidence that EVL treatment has the greatest potential for
improving renal function within the ﬁrst year after cardiac
transplantation [14, 21]. Since EVL is less nephrotoxic than
CNI inhibitors but still has nephrotoxic potential [22], low-
doseEVLmaybemosteﬀectiveinthiscontext.However,this
h a st ob ei n v e s t i g a t e di nf u t u r es t u d i e s .
Our results of unchanged LDL-cholesterol levels and
higher triglyceride levels during follow-up are in line with
earlier results [22]. The large standard deviation of triglyc-
eride levels in the RD group indicates that some patients in
this group obtained very high levels. Again, some patients
seem to be highly responsive to EVL with respect to adverse
eﬀect.
Our study has some limitations. Besides the aforemen-
tioned fact that it was a nonrandomized investigation, some
maycriticizethatweexcludedfromourstudyalargenumber
ofpatientswhowereswitchedovertoEVL.However,thevast
majority of these patients were at high risk of insuﬃcient
immunosuppression due to poor adherence or recurrent
rejection. In these patients, it would have been unethical
to administer a low EVL dose. Instead, all 56 patients with
regular EVL dose who were included in our data analysis
would have had the theoretical chance to receive the low
EVL dose if they would have been switched over at another
point of time. Some may also argue that the follow-up was
restrictedtooneyearonly.However,evenat3yearsoffollow-
up, the two groups did not diﬀer with respect to major
clinical results.
5. Conclusions
The results of our cohort study indicate that low-dose EVL
may be as eﬀective and safe as regular dose EVL.
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